MuReva
Brecksville, US · Founded 2018 · 3 known investors
MuReva Phototherapy develops oral phototherapy devices intended to reduce dose-limiting side effects, such as oral mucositis, in cancer patients undergoing radiation and chemotherapy. Spun off from fiber-optic lighting company Lumitex, its light-transmission technology is being evaluated in a U.S. multicenter clinical trial and is not yet commercially available.
Founders & leadership
Investors · 3
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 1 round · 2018
▶$1.3MraisedDec 2018 · 18 investors · ManufacturingRule 506(b)
▶$1.3MraisedDec 2018 · 18 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- Peter BroerDirector
- Vedang Phototherapy KothariExecutive Officer
- Creighton MurchDirector
- Austin RuhleExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does MuReva do?
- MuReva Phototherapy develops oral phototherapy devices intended to reduce dose-limiting side effects, such as oral mucositis, in cancer patients undergoing radiation and chemotherapy. Spun off from fiber-optic lighting company Lumitex, its light-transmission technology is being evaluated in a U.S. multicenter clinical trial and is not yet commercially available.
- Who are MuReva's investors?
- MuReva's investors include Angel Physicians Fund, Band of Angels, Jumpstart Ventures.
- How much funding has MuReva raised?
- MuReva has disclosed $1.3M raised across 1 round.
- Where is MuReva headquartered?
- MuReva is headquartered in Brecksville, US.